Skip to main content
OpenTrials
Completed

NCT Number: NCT01951274

VPD-737 for Treatment of Chronic Pruritus

A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Pruritus

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Center for Dermatology Clinical Research, Inc., Fremont, California, United States

Loading trial locations.

About this study

The sensation of itch is transmitted to the brain through the nervous system Several chemicals are involved in transmitting this signal This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial The trial will involve once daily pills for 6 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period Patients will also be monitored for safety and will have blood taken for testing and several points during the trial Overall participation will last about 12 weeks

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of chronic pruritus and unresponsive to current therapies

Exclusion criteria

  • Have chronic liver or renal disease

Treatment and study plan

VPD-737

Drug

NK1 Receptor Antagonist

Other names: Serlopitant

Placebo

Drug

Primary outcomes

  1. Visual Analog Scale

    Time frame: 6 weeks

Secondary outcomes

  1. Verbal Response Scale

    Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

Vyne Therapeutics Inc.

Industry

Registry information

Official study title

A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Sep 26, 2013
Registry last updated
May 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.